By Norbert Sparrow -
9 April, 2012
Consumer Reports may have overreached in its recent evaluation of medical products. An article titled "CR Investigates: Dangerous medical devices" is "dangerous reporting" in the view of MD+DI Editor-in-Chief Heather Thompson.
By Norbert Sparrow -
5 March, 2012
The 2.3% excise tax on medical devices that is scheduled to take effect in the United States in 2013 will stifle innovation and kill startups before they can get off the ground, cautions Josh Makower, MD, and CEO and founder of ExploraMed Development.
By Norbert Sparrow -
1 March, 2012
Finland's Tampere University of Technology (TUT) reports that it has developed a biodegradable joint implant, which it believes to be a world first. Used to treat osteoarthritis and rheumatoid arthritis, the RegJoint recently received the CE mark.
By Norbert Sparrow -
22 February, 2012
Germany’s healthcare sector has the potential to overtake automotive as the country’s flagship industry, according to inward investment agency Germany Trade & Invest.
By Norbert Sparrow -
17 February, 2012
A debate comparing the European and US regulatory approval process continues to rage at the Medical Devices Group on LinkedIn.
By Norbert Sparrow -
13 February, 2012
Calling it a "job killer," much of the US medical device industry wants the 2.3% tax on medical devices to be repealed.
By Norbert Sparrow -
10 February, 2012
The European Commission has published a MEDDEV guidance document involving authorised representatives. It is disruptive, writes Erik Vollebregt on his medicaldeviceslegal blog, especially if you did not see it coming. "Everything you know is wrong," writes Vollebregt.
By Norbert Sparrow -
3 February, 2012
European Commission publishes report on faulty French breast implants, draws first lessons from l'affaire Pip.
By Norbert Sparrow -
30 January, 2012
Why medical devices are the future of drugs, according to Dr. Yves Tillet.
By Norbert Sparrow -
23 January, 2012
A panel of CEOs of large medical technology companies at the OneMed event in San Francisco advised smaller companies to stay close to home and leave emerging markets to companies with the resources to play the long game.
